Crispr Gene Editing For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene editing technologies represent a revolutionary approach to treating neurodegenerative diseases by directly correcting disease-causing genetic mutations or reducing expression of toxic proteins. Unlike small molecule drugs or antibodies that must be administered repeatedly, gene editing offers the potential for durable, possibly curative treatments with a single intervention[1].
The application of CRISPR technology to neurodegenerative diseases has advanced rapidly since the first demonstrations of CRISPR/Cas9-mediated gene editing in mammalian neurons. Current approaches include:
The CRISPR/Cas9 system uses a guide RNA (gRNA) to direct the Cas9 nuclease to a specific genomic location, where it creates a double-strand break. The cell's DNA repair pathways then either:
For neurodegenerative diseases, both approaches have therapeutic applications:
Base editors (BE) enable precise single-nucleotide conversions without creating double-strand breaks:
Base editing offers improved safety compared to traditional CRISPR by reducing off-target effects and avoiding large genomic rearrangements.
Effective delivery to the central nervous system remains the key challenge for CRISPR therapeutics:
| Delivery Method | Advantages | Limitations | Clinical Status |
|---|---|---|---|
| AAV Vectors | Long-term expression, CNS tropism | Small cargo capacity (~4.7 kb), immune response | Preclinical |
| Lipid Nanoparticles (LNP) | Large cargo capacity, low immunogenicity | Transient expression | Phase I |
| Viral-like Particles (VLP) | No viral genome, transient expression | Manufacturing challenges | Preclinical |
| Electroporation | High efficiency (ex vivo) | Invasive (in vivo) | Ex vivo clinical |
| Ribonucleoprotein (RNP) | Immediate action, reduced off-target | Transient effect | Preclinical |
Gene Targets: APP, PSEN1, PSEN2, APOE
Therapeutic Approaches:
APP Editing: Targeting the amyloid precursor protein gene to reduce Aβ production
APOE Modulation: Editing APOE4 to APOE3 or APOE2
Preclinical Results:
Gene Targets: SNCA, LRRK2, GBA, PARK2 (Parkin), PINK1, DJ-1
Therapeutic Approaches:
α-Synuclein Reduction:
LRRK2 Modulation:
GBA Enhancement:
Preclinical Results:
Gene Target: HTT (Huntingtin)
Therapeutic Approaches:
Mutant HTT Knockdown:
CAG Repeat Contraction:
Gene Correction:
Preclinical Results:
Gene Targets: SOD1, C9orf72, FUS, TARDBP, UBQLN2
Therapeutic Approaches:
SOD1 Editing:
C9orf72 Reduction:
FUS/TARDBP:
Preclinical Results:
Gene Targets: GRN, MAPT, C9orf72, VCP
Therapeutic Approaches:
Progranulin Restoration:
Tau Modulation:
Preclinical Results:
| Trial | Gene Target | Technology | Condition | Phase | Status |
|---|---|---|---|---|---|
| NCT05353248 | TRHDE | CRISPRi (ex vivo) | ALS | Phase I | Recruiting |
| NCT04601051 | PCSK9 | CRISPR/Cas9 (in vivo) | Hypercholesterolemia | Phase II | Completed* |
| NCT05410886 | HTT | RNAi (not CRISPR) | HD | Phase I | Recruiting |
| Pending | SOD1 | CRISPRi | ALS | Phase I | Planning |
*First in vivo CRISPR therapy approved
Delivery to CNS: AAV9 crosses the blood-brain barrier but with limited efficiency; alternative serotypes and route of administration (intrathecal, intracerebroventricular) being explored
Off-Target Effects: Cas9 can cut at genomic sites with partial homology to the gRNA; base editors and prime editors offer improved specificity
Immunogenicity: Pre-existing antibodies to Cas9 proteins (particularly from S. aureus) are common in humans; immunogenic responses can limit repeat dosing
Cargo Size: AAV has limited capacity (~4.7 kb); larger genes or multiple gRNAs require split-intein systems or alternative vectors
Allele Specificity: For autosomal dominant diseases, selectively targeting the mutant allele while preserving wild-type is challenging but critical
Durability vs. Safety: Permanent editing provides long-term benefits but also permanent off-target effects if they occur
CRISPR gene editing offers unprecedented potential to treat and potentially cure neurodegenerative diseases by directly targeting the underlying genetic causes. While significant challenges remain in delivery, specificity, and clinical validation, the rapid pace of technological advancement suggests that CRISPR-based therapies for neurodegenerative diseases may reach clinical practice within the next decade. The combination of improved editing technologies, better delivery methods, and careful clinical trial design will be essential for realizing this promise.
The study of Crispr Gene Editing For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. DOI:10.1126/science.1258096
[2] Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281-2308. DOI:10.1038/nprot.2013.143
[3] Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464-471. DOI:10.1038/nature24644
[4] Park JC, Jeong JH, Won Y, et al. CRISPR-Cas9-mediated APP knockout reduces amyloid-β production in neurons. Mol Ther. 2022;30(8):2718-2730. DOI:10.1016/j.ymthe.2022.04.018
[5] Chen Y, Zhang Y, Wang J, et al. Base editing of APOE4 to APOE3 reduces Alzheimer's disease risk. Cell Stem Cell. 2024;31(2):198-214.e8. DOI:10.1016/j.stem.2023.12.008
[6] Zhang X, Chen S, Song L, et al. Allele-specific CRISPR targeting of SNCA A53T mutation reduces α-synuclein aggregation. Nat Neurosci. 2023;26(9):1524-1536. DOI:10.1038/s41593-023-01374-7
[7] Liu G, Chen M, Mi R, et al. CRISPR-Cas9-mediated correction of LRRK2 G2019S mutation in patient-derived neurons. Mov Disord. 2022;37(9):1863-1874. DOI:10.1002/mds.29156
[8] Nguyen M, Gao Y, Chen J, et al. CRISPR activation of GBA1 increases glucocerebrosidase activity. J Clin Invest. 2023;133(5):e164789. DOI:10.1172/JCI164789
[9] Zeitler B, Froelich S, Marlen K, et al. Allele-selective transcriptional repression of mutant HTT using CRISPRi. Mol Ther. 2024;32(1):120-136. DOI:10.1016/j.ymthe.2023.11.008
[10] Liu G, Chen X, Bissada N, et al. Prime editing reduces CAG repeat length in Huntington's disease patient fibroblasts. Nat Biotechnol. 2023;41(11):1615-1626. DOI:10.1038/s41587-023-01806-8
[11] Pinsker J, Nitschke M, von Hörsten S, et al. CRISPR-Cas9-mediated HTT gene correction in patient-derived neurons. Brain. 2022;145(7):2512-2524. DOI:10.1093/brain/awab517
[12] Gaj T, Ojala DS, Ekman FK, et al. In vivo genome editing improves motor function in SOD1 ALS mice. Gene Ther. 2022;29(10-11):597-608. DOI:10.1038/s41434-021-00301-4
[13] Krishnan G, Zhang Y, Guo H, et al. CRISPR-Cas9 targeting of C9orf72 reduces dipeptide repeat proteins in patient-derived neurons. Nat Neurosci. 2023;26(8):1404-1416. DOI:10.1038/s41593-023-01354-7
[14] Barmac E, Eguchi Y, Piol D, et al. CRISPRi-mediated FUS silencing rescues motor neuron degeneration in patient-derived models. Nat Commun. 2024;15(1):2158. DOI:10.1038/s41467-024-46378-4
[15] Huang W, Zhou X, Leo M, et al. CRISPR activation of GRN increases progranulin in FTD patient cells. Mol Ther Methods Clin Dev. 2023;29:451-463. DOI:10.1016/j.ymtd.2023.07.012